Anticoagulants in hematologic malignancies: what is the data? Available to Purchase

2.

Ahrari

A

,

Al-Ani

F

,

Wang

YP

,

Lazo-Langner

A.

Treatment of venous thromboembolism in acute leukemia: a systematic review

.

Thromb Res

.

2019

;

178

:

1

-

6

.

3.

Sanfilippo

KM

.

Venous thromboembolism and risk stratification in hematological malignancies

.

Thromb Res

.

2022

;

213

(

Suppl 1

):

S16

-

S21

.

4.

Kashanian

SM

,

Holtzman

NG

,

Patzke

CL

, et al.

Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens

.

Cancer Chemother Pharmacol

.

2021

;

87

(

6

):

817

-

826

.

5.

Ruiz-Llobet

A

,

Gassiot

S

,

Sarrate

E

, et al.

Venous thromboembolism in pediatric patients with acute lymphoblastic leukemia under chemotherapy treatment. Risk factors and usefulness of thromboprophylaxis. Results of LAL-SEHOP-PETHEMA-2013

.

J Thromb Haemost

.

2022

;

20

(

6

):

1390

-

1399

.

6.

Xiao

M

,

Zhou

P

,

Sun

K

.

Effect of therapeutically related drugs on coagulation- anticoagulation balance in acute promyelocytic leukemia

.

Clin Appl Thromb Hemost

.

2022

;

28

:

10760296221080166

.

7.

Poh

C

,

Brunson

A

,

Keegan

T

,

Wun

T

,

Mahajan

A.

Incidence of upper extremity deep vein thrombosis in acute leukemia and effect on mortality

.

TH Open

.

2020

;

4

(

4

):

e309

-

e317

.

8.

Falanga

A

,

Leader

A

,

Ambaglio

C

, et al.

EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer

.

Hemasphere

.

2022

;

6

(

8

):

e750

.

9.

Zwicker

JI

,

Wang

T-F

,

DeAngelo

D-J

, et al.

The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH

.

J Thromb Haemost

.

2020

;

18

(

2

):

278

-

284

.

10.

Gade

IL

,

Riddersholm

SJ

,

Christiansen

I

, et al.

Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study

.

Blood Adv

.

2018

;

2

(

21

):

3025

-

3034

.

11.

Haguet

H

,

Douxfils

J

,

Mullier

F

,

Chatelain

C

,

Graux

C

,

Dogné

J-M

.

Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis

.

Expert Opin Drug Saf

.

2017

;

16

(

1

):

5

-

12

.

12.

Faiz

AS

,

Guo

S

,

Sridharan

A

,

Lin

Y

,

Philipp

CS

.

Risk factors and mortality associated with venous thromboembolism in the elderly US population with chronic lymphocytic leukemia

.

Leuk Res.

2024

;

146

:

107585

.

13.

Wu Y-Y,

Tang

L

,

Wang

M-H

.

Leukemia and risk of venous thromboembolism: a meta-analysis and systematic review of 144 studies comprising 162,126 Patients

.

Sci Rep

.

2017

;

7

(

1

):

1167

.

14.

Essa

H

,

Lodhi

T

,

Dobson

R

,

Wright

D

,

Lip

GYH

.

How to manage atrial fibrillation secondary to ibrutinib

.

JACC CardioOncol

.

2021

;

3

(

1

):

140

-

144

.

15.

Kozhukhov

S

,

Dovganych

N

.

Thromboembolism in patients with cancer: a practical guide to recurrent events

.

Rev Cardiovasc Med

.

2024

;

25

(

11

):

406

.

16.

Hohaus

S

,

Bartolomei

F

,

Cuccaro

A

, et al.

Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis

.

Cancers (Basel)

.

2020

;

12

(

5

):

1291

.

17.

Moik

F

,

Chan

W-E

,

Wiedemann

S

, et al.

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

.

Blood

.

2021

;

137

(

12

):

1669

-

1678

.

18.

van Lent

A

,

Puscasu

R

,

Kaasjager

KAH

, et al.

Venous and arterial thrombosis in patients receiving immune checkpoint inhibitors

.

PLoS One.

2025

;

20

(

4

):

e0321112

.

19.

Schmidt

RA

,

Lee

AYY

.

How I treat and prevent venous thrombotic complications in patients with lymphoma

.

Blood

.

2022

;

139

(

10

):

1489

-

1500

.

20.

Lyman

GH

,

Carrier

M

,

Ay

C

, et al.

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

.

Blood Adv

.

2021

;

5

(

4

):

927

-

974

.

21.

Gidaro

A

,

Manetti

R

,

Delitala

AP

, et al.

Incidence of venous thromboembolism in multiple myeloma patients across different regimens: role of procoagulant microparticles and cytokine release

.

J Clin Med

.

2022

;

11

(

10

):

2720

.

22.

Li

P

,

Xu

B

,

Xu

J

, et al.

Lenalidomide promotes thrombosis formation, but does not affect platelet activation in multiple myeloma

.

Int J Mol Sci

.

2023

;

24

(

18

):

14097

.

23.

De Stefano

V

,

Larocca

A

,

Carpenedo

M

, et al.

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel

.

Haematologica

.

2022

;

107

(

11

):

2536

-

2547

.

24.

Zweegman

S

,

van de Donk

NWCJ

.

Supportive care in myeloma—when treating the clone alone is not enough

.

Hematology Am Soc Hematol Educ Program

.

2024

;

2024

(

1

):

569

-

581

.

25.

Elshoury

A

,

Schaefer

JK

,

Lim

MY

,

Skalla

DP

,

Streiff

MB

.

Update on guidelines for the prevention of cancer-associated thrombosis

.

J Natl Compr Canc Netw.

2022

;

20

(

13

).

26.

Schrag

D

,

Uno

H

,

Rosovsky

R

, et al;

CANVAS Investigators

.

Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial

.

JAMA

.

2023

;

329

(

22

):

1924

-

1933

.

27.

Benfield

M

,

He

J

,

Arnall

J

, et al.

Venous thromboembolism incidence and risk factors in patients undergoing hematopoietic stem cell transplantation

.

Transplant Cell Ther.

2025

;

31

(

2

):111.e1-111111.e10.

28.

Ranalli

P

,

Ten Cate

H.

Venous thromboembolism prophylaxis after hematopoietic cell transplantation: still a challenge for hematologists and hemostasiologists

.

Thromb Haemost

.

2025

;

125

(

2

):

163

-

165

.

29.

Baljevic

M

,

Sborov

DW

.

Understanding risks and refining strategies for thromboembolism prophylaxis in hematopoietic stem cell transplant recipients

.

Bone Marrow Transplant

.

2023

;

58

(

11

):

1177

-

1178

.

30.

El Jurdi

N

,

Elhusseini

H

,

Beckman

J

, et al.

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group

.

Blood Cancer J

.

2021

;

11

(

5

):

96

.

31.

Zahid

MF

,

Murad

MH

,

Litzow

MR

, et al.

Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis

.

Ann Hematol

.

2016

;

95

(

9

):

1457

-

1464

.

32.

Evangelidis

P

,

Gavriilaki

E

,

Tsakiris

DA

.

Thrombotic complications after hematopoietic stem cell transplantation and other cellular therapies

.

Thrombosis Update

.

2024

;

16

:

100186

.

33.

Schorr

C

,

Forindez

J

,

Espinoza-Gutarra

M

,

Mehta

R

,

Grover

N

,

Perna

F

.

Thrombotic events are unusual toxicities of chimeric antigen receptor T-cell therapies

.

Int J Mol Sci

.

2023

;

24

(

9

):

8349

.

34.

Peng

X

,

Zhang

X

,

Zhao

M

, et al.

Coagulation abnormalities associated with CAR-T-cell therapy in haematological malignancies: a review

.

Br J Haematol

.

2024

;

205

(

2

):

420

-

428

.

35.

Bindal

P

,

Patell

R

,

Chiasakul

T

, et al.

A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

.

J Thromb Haemost

.

2024

;

22

(

7

):

2071

-

2080

.

36.

Frere

C

,

Font

C

,

Esposito

F

,

Crichi

B

,

Girard

P

,

Janus

N.

Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis

.

Supportive Care Cancer

.

2022

;

30

(

4

):

2919

-

2931

.

37.

Fujisaki

T

,

Sueta

D

,

Yamamoto

E

, et al.

Comparing anticoagulation strategies for venous thromboembolism associated with active cancer: a systematic review and meta-analysis

.

JACC CardioOncol

.

2024

;

6

(

1

):

99

-

113

.

38.

Khorana

AA

,

Soff

GA

,

Kakkar

AK

, et al.

Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer

.

N Engl J Med

.

2019

;

380

(

8

):

720

-

728

.

39.

Key

NS

,

Khorana

AA

,

Kuderer

NM

, et al.

Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update

.

J Clin Oncol

.

2020

;

38

(

5

):

496

-

520

.

40.

Moik

F

,

Colling

M

,

Mahé

I

,

Jara-Palomares

L

,

Pabinger

I

,

Ay

C.

Extended anticoagulation treatment for cancer-associated thrombosis—Rates of recurrence and bleeding beyond 6 months: a systematic review

.

J Thromb Haemost

.

2022

;

20

(

3

):

619

-

634

.

41.

Grdinic

AG

,

Radovanovic

S

,

Gleditsch

J

, et al.

Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy

.

J Thromb Haemost

.

2024

;

22

(

4

):

1094

-

1104

.

42.

Mulder

FI

,

Bosch

FTM

,

Carrier

M

, et al.

Growth differentiation factor-15 for prediction of bleeding in cancer patients

.

J Thromb Haemost

.

2022

;

20

(

1

):

138

-

144

.

43.

Byrd

JC

,

Hillmen

P

,

Ghia

P

, et al.

Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial

.

J Clin Oncol

.

2021

;

39

(

31

):

3441

-

3452

.

44.

Miller

G

,

Reynolds

SB

,

Tse

WW

.

Case report management of thrombocytopenia in a patient with a mechanical mitral valve undergoing autologous hematopoietic stem cell transplantation: case report and review of literature

.

Am J Blood Res

.

2020

;

10

(

1

):

11

-

14

.

45.

Kearon

C

,

Akl

EA

,

Ornelas

J

, et al.

Antithrombotic therapy for VTE disease

.

Chest

.

2016

;

149

(

2

):

315

-

352

.

46.

Kawano

N

,

Fukatsu

M

,

Yamakawa

K

, et al.

A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies

.

Int J Hematol

.

2024

;

119

(

4

):

416

-

425

.

47.

Ikezoe

T.

Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies

.

Int J Hematol

.

2021

;

113

(

1

):

34

-

44

.

48.

Swartz

AW

,

Drappatz

J.

Safety of direct oral anticoagulants in central nervous system malignancies

.

Oncologist

.

2021

;

26

(

5

):

427

-

432

.

49.

Farge

D

,

Frere

C

,

Connors

JM

, et al.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

.

Lancet Oncol

.

2022

;

23

(

7

):

e334

-

e347

.

50.

Chopra

V

,

Anand

S

,

Hickner

A

, et al.

Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis

.

Lancet

.

2013

;

382

(

9889

):

311

-

325

.

51.

Bahl

A

,

Mielke

N

,

Xing

Y.

Risk of midline catheter-related thrombosis due to catheter diameter: an observational cohort study

.

Thromb Res

.

2023

;

228

:

172

-

180

.

52.

Streiff

MB

,

Holmstrom

B

,

Angelini

D

, et al.

Cancer-associated venous thromboembolic disease, version 2.2024

.

J Natl Compr Canc Netw

.

2024

;

22

(

7

):

483

-

506

.

53.

Al-Azzawi

HMA

,

Hamza

SA

,

Paolini

R

, et al.

Towards an emerging role for anticoagulants in cancer therapy: a systematic review and meta-analysis

.

Frontiers in Oral Health

.

2024

;

5

:

1

-

19

.

54.

Russo

V

,

Falco

L

,

Tessitore

V

, et al.

Anti-inflammatory and anticancer effects of anticoagulant therapy in patients with malignancy

.

Life

.

2023

;

13

(

9

):

1

-

19

.

55.

Tatsumi

K.

The pathogenesis of cancer-associated thrombosis

.

Int J Hematol

.

2024

;

119

(

5

):

495

-

504

.

56.

Comerford

C

,

Glavey

S

,

Quinn

J

,

O'Sullivan

JM

.

The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies

.

J Thromb Haemost

.

2022

;

20

(

8

):

1766

-

1777

.

57.

Jalaber

E

,

Orvain

C

,

Papadopoulou

V

, et al.

Management of thrombocytopenia and anticoagulant therapy in patients with hematological malignancy on chemotherapy: a binational prospective study (TAT study)

.

J Thromb Thrombolysis

.

2025

;

58

(

5

):

646

-

656

.

58.

Lohr

LK

,

Blake

KT

,

Chan

CM

,

Sturm

S

,

Walsh

GT

.

Managing drug interactions with oral anticancer treatments

.

J Adv Pract Oncol

.

2023

;

14

(

5

):

419

-

438

.

59.

Mulder

FI

,

Candeloro

M

,

Kamphuisen

PW

, et al.

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis

.

Haematologica

.

2019

;

104

(

6

):

1277

-

1287

.

60.

Khorana

AA

,

Kuderer

NM

,

Culakova

E

,

Lyman

GH

,

Francis

CW

.

Development and validation of a predictive model for chemotherapy-associated thrombosis

.

Blood

.

2008

;

111

(

10

):

4902

-

4907

.

61.

EL-Sayed

HA

,

Othman

M

,

Azzam

H

, et al.

Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models

.

J Cancer Res Clin Oncol

.

2023

;

149

(

20

):

17771

-

17780

.

62.

Rupa-Matysek

J

,

Brzeźniakiewicz-Janus

K

,

Gil

L

,

Krasiński

Z

,

Komarnicki

M.

Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice

.

Cancer Med

.

2018

;

7

(

7

):

2868

-

2875

.

63.

Liang

G

,

Li

X

,

Xu

Q

, et al.

Development and validation of a nomogram model for predicting the risk of venous thromboembolism in lymphoma patients undergoing chemotherapy: a prospective cohort study conducted in China

.

Ann Med

.

2023

;

55

(

2

):

1

-

9

.

64.

Mitrovic

M

,

Pantic

N

,

Bukumiric

Z

, et al.

Venous thromboembolism in patients with acute myeloid leukemia: development of a predictive model

.

Thromb J

.

2024

;

22

(

1

):

1

-

10

.

65.

Sanfilippo

KM

,

Luo

S

,

Wang

TF

, et al.

Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score

.

Am J Hematol

.

2019

;

94

(

11

):

1176

-

1184

.

66.

Li

A

,

Wu

Q

,

Luo

S

, et al.

Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma

.

J Natl Compr Canc Netw

.

2019

;

17

(

7

):

840

-

847

.

67.

Streiff

MB

,

Holmstrom

B

,

Angelini

D

, et al.

Cancer-associated venous thromboembolic disease, version 2.2021

.

J Natl Compr Canc Netw

.

2021

;

19

(

10

):

1181

-

1201

.

68.

Chakraborty

R

,

Rybicki

L

,

Wei

W

, et al.

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

.

Blood

.

2022

;

140

(

23

):

2443

-

2450

.

69.

Sekar

A

,

Ramasamy

C

,

Geetha

HS

, et al.

External validation of PRISM score in multiple myeloma patients in a community setting: a retrospective cohort study

.

Blood

.

2023

;

142

(

Suppl 1

):

4721

.